about
Cytochrome P4502C9: an enzyme of major importance in human drug metabolismWarfarin therapy: in need of improvement after all these years.Effect of age and sex on warfarin dosingRealities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation.The future prospects of pharmacogenetics in oral anticoagulation therapy.Oral anticoagulation in paediatric patients: dose requirements and complications.Genetic warfarin dosing: tables versus algorithms.A patient-centered approach to the development and pilot of a warfarin pharmacogenomics patient education tool for health professionalsStatistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to AnalysisPharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.The pharmacogenetics of coumarin therapy.The risks of warfarin use in the elderly.Effect of patient-specific factors on weekly warfarin doseDosing algorithms to predict warfarin maintenance dose in Caucasians and African AmericansFluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated.Role of warfarin pharmacogenetic testing in clinical practice.A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk.Patient factors that influence warfarin dose response.Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Pharmacogenetic biomarkers for predicting drug response.Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.Factors affecting the maintenance dose of warfarinThe effect of carbamazepine on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance.In silico pharmacogenetics of warfarin metabolism.Pharmacogenetics of coumarinic oral anticoagulants.Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.The association of vitamin K status with warfarin sensitivity at the onset of treatment.Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements.The use of oral anticoagulants (warfarin) in older people. American Geriatrics Society guideline.Patient-specific factors predictive of warfarin dosage requirements.
P2860
Q24683497-6E0F2D8F-E9AA-4652-AE61-96BDB3A06FDFQ33793086-1B8FEF4C-5142-419A-A103-1F6B72355726Q33921765-4A933D01-A848-460B-92F3-93EC30D7916DQ34131354-18E4D771-7AEB-40F9-A0B6-92DA821FE925Q34252907-0FCC2DB8-E264-4F1E-AFFD-E695F87CDD22Q34346399-6475FA2C-31B4-4507-AD0C-0393AB674C3CQ34472581-B1BE037D-3E23-4A03-A282-5468CA0753FFQ34530230-E26E8C4F-9E7F-4C3F-8C9E-0BC4B11175FCQ34797728-B3977EE5-9EAC-4F9E-AF62-45E31F52B6C8Q35021027-BA5B94F3-7749-4989-B9C9-C3050A57257CQ35116407-C4EF731A-44FC-452F-8962-CFC1335FF67CQ35185164-A0C6CB64-3F58-48AF-9F69-FCC66F0323F8Q35204081-2A6A0265-F98A-4E35-BB1D-C7113149932AQ35790384-B84FCCF7-6966-4458-82C7-F3B1DA2F0477Q35873687-276EED97-B0A1-4175-9FE7-38B175C4BA8EQ36087965-6BFECB4D-3A94-4F05-821B-71F8A0FA7F09Q36192806-9237F0A0-E265-4526-AA91-AB0A6351ACF1Q36446904-54095114-9333-4C9E-8DB6-37B8397FF58BQ36661285-5A7B81C3-7D05-478A-8920-D657337C0A80Q36882317-3499BCBF-9C53-4C60-8D6F-9493C5E2A918Q37608475-C818766F-D083-4220-A609-37734B1FEA35Q37733582-698726B9-9FB8-4D2E-A9BE-5770FA564CDDQ37770117-FC262EB8-FA44-4609-B359-6D351B21FFBFQ37777419-35120C0F-DD36-4833-A8B3-81682820BD23Q37867275-432C0DCD-57D6-477B-BA5E-2E0BEB5CF2C8Q38042441-030C4FEC-D8E7-4EBB-97E1-C6456A10B791Q38214388-0630FB92-3C62-4480-9024-7D2A77BBB009Q38897899-3A6A36FF-CECD-4C0A-8200-6C553E37DA48Q38897904-B6D5C87C-3BC1-4315-977A-5759C0778BBFQ39612514-073BD776-F535-4D3E-B14F-F0A98BB84310Q40081501-7CDACDF5-D15F-4AAF-AD5E-09B2E5145001Q40425835-60A9D1A0-FF7E-4D72-9A55-81ACFB803333Q41009890-63A64EBE-EEAD-459C-A441-F9DFC3BF4D78Q41894196-476BE4E5-B85F-4095-A8BD-146DBEC9E396Q43115875-90E5904C-EFAD-4DB5-994C-7B73BD3F5119Q43258272-A4171EA9-BEC4-4DCF-A941-C1555413BA42Q43548649-987F1867-9513-4514-9DE5-D5614AF1D08CQ43926562-B22FC9D2-670F-41D0-99D2-F1A810A00476Q44091776-CE96B7A9-234C-40DE-8047-04D328F7F5A2Q44146616-0AC6E52E-216B-42FD-BBCC-6ADD7149B31E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1992
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Factors affecting the maintenance dose of warfarin.
@en
type
label
Factors affecting the maintenance dose of warfarin.
@en
prefLabel
Factors affecting the maintenance dose of warfarin.
@en
P2093
P2860
P356
P1476
Factors affecting the maintenance dose of warfarin.
@en
P2093
P2860
P304
P356
10.1136/JCP.45.8.704
P407
P577
1992-08-01T00:00:00Z